Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AXSM Axsome Therapeutics	$103.02 +1.6%	$105.84	$72.21 ▼ $139.13	$4.99B	0.51	635,684 shs	838,764 shs
COGT Cogent Biosciences	$11.40 -0.2%	$8.62	$3.72 ▼ $12.97	$1.30B	0.35	4.80 million shs	1.47 million shs
LNTH Lantheus	$70.57 -0.9%	$77.65	$69.12 ▼ $118.21	$4.93B	0.14	1.02 million shs	943,059 shs
TLX Telix Pharmaceuticals	$13.05 -4.0%	$16.05	$12.90 ▼ $30.36	$4.60B	N/A	56,084 shs	55,378 shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AXSM Axsome Therapeutics	+1.62%	+2.17%	-0.86%	-8.19%	+17.99%
COGT Cogent Biosciences	-0.18%	-5.55%	+53.85%	+94.21%	+20.89%
LNTH Lantheus	-0.87%	-3.24%	-11.37%	-35.10%	-32.68%
TLX Telix Pharmaceuticals	-3.97%	-8.10%	-20.91%	-30.21%	+1,304,999,900.00%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AXSM Axsome Therapeutics	4.8236 of 5 stars	4.5	3.0	0.0	4.5	2.9	4.2	0.6
COGT Cogent Biosciences	2.8806 of 5 stars	4.4	1.0	0.0	0.0	2.4	1.7	0.6
LNTH Lantheus	4.6193 of 5 stars	3.4	3.0	0.0	4.2	3.3	2.5	1.9
TLX Telix Pharmaceuticals	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AXSM Axsome Therapeutics	3.06	Buy	$172.33	67.28% Upside
COGT Cogent Biosciences	2.82	Moderate Buy	$18.70	64.04% Upside
LNTH Lantheus	2.83	Moderate Buy	$131.20	85.91% Upside
TLX Telix Pharmaceuticals	3.00	Buy	$22.33	71.14% Upside

Current Analyst Ratings Breakdown

Latest COGT, LNTH, AXSM, and TLX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/18/2025	COGT Cogent Biosciences	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$15.00 ➝ $22.00
7/16/2025	LNTH Lantheus	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Perform
7/10/2025	COGT Cogent Biosciences	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Overweight ➝ Overweight	$25.00 ➝ $29.00
7/9/2025	TLX Telix Pharmaceuticals	William Blair Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Outperform
7/8/2025	COGT Cogent Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$12.00 ➝ $22.00
7/8/2025	COGT Cogent Biosciences	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$17.00
7/8/2025	COGT Cogent Biosciences	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Neutral ➝ Neutral	$7.00 ➝ $9.00
7/7/2025	COGT Cogent Biosciences	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$23.00 ➝ $28.00
7/7/2025	COGT Cogent Biosciences	Leerink Partners Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$16.00 ➝ $18.00
7/3/2025	AXSM Axsome Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Overweight	$190.00
7/3/2025	TLX Telix Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$23.00

(Data available from 8/2/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AXSM Axsome Therapeutics	$385.69M	13.15	N/A	N/A	$1.18 per share	87.31
COGT Cogent Biosciences	N/A	N/A	N/A	N/A	$1.32 per share	N/A
LNTH Lantheus	$1.53B	3.18	$7.04 per share	10.03	$15.65 per share	4.51
TLX Telix Pharmaceuticals	$516.72M	8.55	$0.11 per share	119.01	$1.12 per share	11.65

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AXSM Axsome Therapeutics	-$287.22M	-$5.77	N/A	36.53	N/A	-64.39%	-272.80%	-36.69%	8/4/2025 (Estimated)
COGT Cogent Biosciences	-$255.86M	-$1.84	N/A	N/A	N/A	N/A	-149.79%	-75.61%	8/5/2025 (Estimated)
LNTH Lantheus	$312.44M	$3.52	20.05	11.18	N/A	16.55%	36.99%	20.55%	8/6/2025 (Estimated)
TLX Telix Pharmaceuticals	$32.93M	N/A	0.00	27.19	N/A	N/A	N/A	N/A	8/20/2025 (Estimated)

Latest COGT, LNTH, AXSM, and TLX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/20/2025	H1 2025	TLX Telix Pharmaceuticals	$0.2160	N/A	N/A	N/A	$316.69 million	N/A
8/6/2025	Q2 2025	LNTH Lantheus	$1.65	N/A	N/A	N/A	$389.69 million	N/A
8/5/2025	Q2 2025	COGT Cogent Biosciences	-$0.54	N/A	N/A	N/A	N/A	N/A
8/4/2025	Q2 2025	AXSM Axsome Therapeutics	-$1.04	N/A	N/A	N/A	$140.02 million	N/A
5/7/2025	Q1 2025	LNTH Lantheus	$1.64	$1.53	-$0.11	$1.02	$377.37 million	$372.76 million
5/6/2025	Q1 2025	COGT Cogent Biosciences	-$0.56	-$0.52	+$0.04	-$0.52	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AXSM Axsome Therapeutics	N/A	N/A	N/A	N/A	N/A
COGT Cogent Biosciences	N/A	N/A	N/A	N/A	N/A
LNTH Lantheus	N/A	N/A	N/A	N/A	N/A
TLX Telix Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AXSM Axsome Therapeutics	3.48	2.03	1.96
COGT Cogent Biosciences	N/A	5.13	5.13
LNTH Lantheus	0.49	5.74	5.46
TLX Telix Pharmaceuticals	0.99	2.78	2.66

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AXSM Axsome Therapeutics	81.49%
COGT Cogent Biosciences	N/A
LNTH Lantheus	99.06%
TLX Telix Pharmaceuticals	N/A

Insider Ownership

Company	Insider Ownership
AXSM Axsome Therapeutics	22.30%
COGT Cogent Biosciences	7.29%
LNTH Lantheus	1.50%
TLX Telix Pharmaceuticals	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AXSM Axsome Therapeutics	380	49.24 million	38.26 million	Optionable
COGT Cogent Biosciences	80	113.86 million	105.56 million	Optionable
LNTH Lantheus	700	69.19 million	68.15 million	Optionable
TLX Telix Pharmaceuticals	N/A	338.40 million	N/A	N/A

COGT, LNTH, AXSM, and TLX Headlines

Recent News About These Companies

TLX Investors Have Opportunity to Join Telix Pharmaceuticals Limited Fraud Investigation with the Schall Law Firm

July 31 at 2:19 PM | businesswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited - TLX

July 31 at 10:00 AM | prnewswire.com

Telix Pharmaceuticals Limited (TLX) Shares Fall Amid SEC Subpoena -- Hagens Berman

July 31 at 9:20 AM | prnewswire.com

Telix Pharmaceuticals (NASDAQ:TLX) Reaches New 1-Year Low - Should You Sell?

July 30 at 12:40 PM | marketbeat.com

Telix H1 2025 Results: Investor Webcast Notification

July 29, 2025 | globenewswire.com

Telix Pharmaceuticals Limited (TLX) Shares Fall Amid SEC Subpoena -- Hagens Berman

July 29, 2025 | globenewswire.com

Telix Pharmaceuticals: Assessing The Market's Pullback On SEC Inquiry

July 29, 2025 | seekingalpha.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited – TLX

July 28, 2025 | globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Telix Pharmaceuticals Limited - TLX

July 27, 2025 | prnewswire.com

William Blair Issues Optimistic Forecast for TLX Earnings

July 26, 2025 | americanbankingnews.com

Telix Pharmaceuticals (NASDAQ:TLX) Sees Strong Trading Volume - What's Next?

July 25, 2025 | marketbeat.com

Telix Pharmaceuticals Limited (TLX) Investors Who Lost Money - Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

July 24, 2025 | tmcnet.com

Securities Fraud Investigation Into Telix Pharmaceuticals Limited (TLX) Announced – Investors Who Lost Money Urged To Contact Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm

July 24, 2025 | businesswire.com

Telix Pharmaceuticals Limited (TLX) Investors Who Lost Money – Contact Law Offices of Howard G. Smith About Securities Fraud Investigation

July 24, 2025 | businesswire.com

Telix Pharmaceuticals (NASDAQ:TLX) Shares Gap Down - Here's Why

July 24, 2025 | marketbeat.com

Equities Analysts Offer Predictions for TLX FY2025 Earnings

July 24, 2025 | marketbeat.com

INVESTOR ALERT: Investigation of Telix Pharmaceuticals Limited (TLX) Announced by Holzer & Holzer, LLC

July 23, 2025 | globenewswire.com

Securities Fraud Investigation Into Telix Pharmaceuticals Limited (TLX) Announced â€“ Investors Who Lost Money Urged To Contact The Law Offices of Frank R. Cruz

July 23, 2025 | businesswire.com

Telix Pharmaceuticals stock drops as SEC probes disclosures tied to cancer treatment

July 23, 2025 | msn.com

Telix sinks as US regulator SEC issues subpoena over claims

July 23, 2025 | msn.com

Why did the Telix share price just crash 16%?

July 23, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

COGT, LNTH, AXSM, and TLX Company Descriptions

Axsome Therapeutics NASDAQ:AXSM

$103.02 +1.64 (+1.62%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$104.02 +1.01 (+0.98%)

As of 08/1/2025 07:59 PM Eastern

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Cogent Biosciences NASDAQ:COGT

$11.40 -0.02 (-0.18%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$11.90 +0.50 (+4.43%)

As of 08/1/2025 05:07 PM Eastern

Cogent Biosciences, Inc., a biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor designed to target mutations within the KIT receptor tyrosine kinase, including KIT D816V KIT D816V mutation that drives systemic mastocytosis, as well as other mutations in KIT exon 17, which are found in patients with advanced gastrointestinal stromal tumors. The company has a licensing agreement with Plexxikon Inc. for the research, development, and commercialization of bezuclastinib. The company was formerly known as Unum Therapeutics Inc. and changed its name to Cogent Biosciences, Inc. in October 2020. Cogent Biosciences, Inc. was incorporated in 2014 and is headquartered in Waltham, Massachusetts.

Lantheus NASDAQ:LNTH

$70.57 -0.62 (-0.87%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$70.74 +0.17 (+0.23%)

As of 08/1/2025 07:51 PM Eastern

Lantheus Holdings, Inc. develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer. The company also offers Automated Bone Scan Index that calculates the disease burden of prostate cancer by detecting and classifying bone scan tracer uptakes as metastatic or benign lesions using an artificial neural network; RELISTOR for opioid-induced constipation; and aPROMISE, an artificial intelligence medical device software; and PYLARIFY AI, an AI-based medical device software to perform quantitative assessment of PSMA PET/CT images in prostate cancer. In addition, it develops 1095, a PSMA-targeted iodine-131-labeled small molecule; PNT2002, a radiopharmaceutical therapy to treat mCRPC; PNT2003, an SSTR therapy that treats patients with SSTR-positive neuroendocrine tumors; MK-6240, a F 18-labeled PET imaging agent that targets Tau tangles in Alzheimer's disease; LNTH-1363S, an fibroblast activation protein, alpha targeted, copper-64 labeled PET imaging agent; and flurpiridaz used to assess blood flow to the heart;. It has collaboration agreements with GE Healthcare; NanoMab Technology Limited; Curium; RefleXion Medical, Inc.; POINT; Regeneron Pharmaceuticals, Inc; and Ratio Therapeutics LLC. The company was founded in 1956 and is based in Bedford, Massachusetts.

Telix Pharmaceuticals NASDAQ:TLX

$13.05 -0.54 (-3.97%)

Closing price 08/1/2025 04:00 PM Eastern

Extended Trading

$13.05 0.00 (0.00%)

As of 08/1/2025 06:05 PM Eastern

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals. The Product Development segment develops radiopharmaceutical products for commercialization. It focuses on cancer care, specifically in prostate, renal or kidney and glioblastoma or brain cancer. Its products include TLX250, TLX591, and TLX101. The company was founded by Andreas Kluge and Christian P. Behrenbruch in November 2015 and is headquartered in Melbourne, Australia.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time